Literature DB >> 28905282

Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.

D Shepshelovich1,2,3, H Goldvaser1,2,3, L Wang1, A R Abdul Razak1,3, P L Bedard4,5.   

Abstract

Background Data on completeness of reporting of phase I cancer clinical trials in publications are lacking. Methods The ClinicalTrials.gov database was searched for completed adult phase I cancer trials with reported results. PubMed was searched for matching primary publications published prior to November 1, 2016. Reporting in primary publications was compared with the ClinicalTrials.gov database using a 28-point score (2=complete; 1=partial; 0=no reporting) for 14 items related to study design, outcome measures and safety profile. Inconsistencies between primary publications and ClinicalTrials.gov were recorded. Linear regression was used to identify factors associated with incomplete reporting. Results After a review of 583 trials in ClinicalTrials.gov , 163 matching primary publications were identified. Publications reported outcomes that did not appear in ClinicalTrials.gov in 25% of trials. Outcomes were upgraded, downgraded or omitted in publications in 47% of trials. The overall median reporting score was 23/28 (interquartile range 21-25). Incompletely reported items in >25% publications were: inclusion criteria (29%), primary outcome definition (26%), secondary outcome definitions (53%), adverse events (71%), serious adverse events (80%) and dates of study start and database lock (91%). Higher reporting scores were associated with phase I (vs phase I/II) trials (p<0.001), multicenter trials (p<0.001) and publication in journals with lower impact factor (p=0.004). Conclusions Reported results in primary publications for early phase cancer trials are frequently inconsistent or incomplete compared with ClinicalTrials.gov entries. ClinicalTrials.gov may provide more comprehensive data from new cancer drug trials.

Entities:  

Keywords:  Cancer; ClinicalTrials.gov; Phase I; Publications; Reporting

Mesh:

Year:  2017        PMID: 28905282     DOI: 10.1007/s10637-017-0510-8

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  26 in total

1.  Presentation and subsequent publication rates of phase I oncology clinical trials.

Authors:  Luis H Camacho; Jennifer Bacik; Alexander Cheung; David R Spriggs
Journal:  Cancer       Date:  2005-10-01       Impact factor: 6.860

Review 2.  Relevance of randomised controlled trials in oncology.

Authors:  Ian F Tannock; Eitan Amir; Christopher M Booth; Saroj Niraula; Alberto Ocana; Bostjan Seruga; Arnoud J Templeton; Francisco Vera-Badillo
Journal:  Lancet Oncol       Date:  2016-12       Impact factor: 41.316

Review 3.  Prevention of selective outcome reporting: let us start from the beginning.

Authors:  Rafael Dal-Ré; Ana Marušić
Journal:  Eur J Clin Pharmacol       Date:  2016-08-02       Impact factor: 2.953

4.  Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.

Authors:  Ethan Basch; Alexia Iasonos; Tiffani McDonough; Allison Barz; Ann Culkin; Mark G Kris; Howard I Scher; Deborah Schrag
Journal:  Lancet Oncol       Date:  2006-11       Impact factor: 41.316

Review 5.  Adverse event reporting in cancer clinical trial publications.

Authors:  Shanthi Sivendran; Asma Latif; Russell B McBride; Kristian D Stensland; Juan Wisnivesky; Lindsay Haines; William K Oh; Matthew D Galsky
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

6.  Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire.

Authors:  M Cirillo; M Venturini; L Ciccarelli; F Coati; O Bortolami; G Verlato
Journal:  Ann Oncol       Date:  2009-07-17       Impact factor: 32.976

7.  Comparison of Eligibility Criteria Between Protocols, Registries, and Publications of Cancer Clinical Trials.

Authors:  Sheng Zhang; Fei Liang; Wenfeng Li; Ian Tannock
Journal:  J Natl Cancer Inst       Date:  2016-05-25       Impact factor: 13.506

Review 8.  Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies.

Authors:  A Srikanthan; F Vera-Badillo; J Ethier; R Goldstein; A J Templeton; A Ocana; B Seruga; E Amir
Journal:  Cancer Treat Rev       Date:  2015-12-31       Impact factor: 12.111

Review 9.  Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review.

Authors:  Kerry Dwan; Carrol Gamble; Paula R Williamson; Jamie J Kirkham
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

10.  Association between trial registration and treatment effect estimates: a meta-epidemiological study.

Authors:  Agnès Dechartres; Philippe Ravaud; Ignacio Atal; Carolina Riveros; Isabelle Boutron
Journal:  BMC Med       Date:  2016-07-04       Impact factor: 8.775

View more
  2 in total

Review 1.  Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database.

Authors:  D Shepshelovich; H Goldvaser; L Wang; A R Abdul Razak
Journal:  Invest New Drugs       Date:  2017-12-13       Impact factor: 3.850

2.  Inadequate reporting quality of registered genome editing trials: an observational study.

Authors:  Diana Jurić; Michael Zlatin; Ana Marušić
Journal:  BMC Med Res Methodol       Date:  2022-05-02       Impact factor: 4.612

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.